Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been assigned an average recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $62.33.

A number of research firms have recently commented on EGRX. Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 9th. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $75.00 price objective (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Finally, Mizuho reissued a “sell” rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th.

Eagle Pharmaceuticals (EGRX) traded down $0.47 during trading hours on Tuesday, hitting $62.09. 319,800 shares of the stock were exchanged, compared to its average volume of 214,067. The company has a market cap of $926.48, a P/E ratio of 10.01 and a beta of 1.24. Eagle Pharmaceuticals has a one year low of $45.05 and a one year high of $97.15. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.50. Eagle Pharmaceuticals had a net margin of 36.95% and a return on equity of 62.60%. equities research analysts predict that Eagle Pharmaceuticals will post 2.23 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Municipal Employees Retirement System of Michigan lifted its holdings in Eagle Pharmaceuticals by 68.1% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after purchasing an additional 1,300 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Eagle Pharmaceuticals by 58.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock valued at $194,000 after acquiring an additional 908 shares in the last quarter. Schroder Investment Management Group acquired a new stake in Eagle Pharmaceuticals in the 3rd quarter valued at about $219,000. Foundry Partners LLC acquired a new stake in Eagle Pharmaceuticals in the 3rd quarter valued at about $224,000. Finally, Kopp Investment Advisors LLC increased its position in Eagle Pharmaceuticals by 0.3% in the 2nd quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 10 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/16/eagle-pharmaceuticals-inc-egrx-receives-consensus-recommendation-of-hold-from-analysts.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.